Manatt Health managing director Jocelyn Guyer spoke with Bloomberg Law about the Substance Abuse and Mental Health Services Administration’s decision to relax patient eligibility regulations for take-home medication for those recovering from opioid addiction in response to the COVID-19 pandemic. In the article, Guyer notes that the updated guidance, which would allow more patients to take home their methadone and other treatment drugs instead of receiving them in an opioid clinic, may lead to negative outcomes for the affected patients. “It’s a perfect storm of what you do not want during a public health epidemic,” she said.
Read the article here.